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AbstrACt
background Non-communicable diseases (NCDs) 
contribute greatly to morbidity and mortality in low-
income and middle-income countries (LMICs). Community 
health workers (CHWs) may improve disease control and 
medication adherence among patients with NCDs in LMICs, 
but data are lacking. We assessed the impact of a CHW-
led intervention on disease control and adherence among 
patients with diabetes and/or hypertension in Chiapas, 
Mexico.
Methods We conducted a prospective observational study 
among adult patients with diabetes and/or hypertension, 
in the context of a stepped-wedge roll-out of a CHW-led 
intervention. We measured self-reported adherence to 
medications, blood pressure and haemoglobin A1c at 
baseline and every 3 months, timed just prior to expansion 
of the intervention to a new community. We conducted 
individual-level mixed effects analyses of study data, 
adjusting for time and clustering by patient and community. 
Findings We analysed 108 patients. The CHW-led 
intervention was associated with a twofold increase in the 
odds of disease control (OR 2.04, 95% CI 1.15 to 3.62). It 
was also associated with optimal adherence assessed by 
30-day recall (OR 1.86; 95% CI 1.15 to 3.02) and a positive 
self-assessment of adherence behaviour (OR 2.29; 95% CI 
1.26 to 4.15), but not by 5-day recall.
Interpretation A CHW-led adherence intervention was 
associated with disease control and adherence among 
adults with diabetes and/or hypertension. This study 
supports a role of CHWs in supplementing comprehensive 
primary care for patients with NCDs in LMICs.
trial registration number NCT02549495.
IntroduCtIon
WHO identifies the rising prevalence of 
non-communicable diseases (NCDs) such 
as type II diabetes mellitus (diabetes) and 
cardiovascular disease as a major challenge 
for social and economic development in the 
21st century.1 2 Patients in low-income and 
middle-income countries (LMICs) bear a 
disproportionate burden of morbidity and 
mortality from NCDs,2 and within-LMICs, 
patients with lower socioeconomic status have 
worse NCD outcomes and a higher prevalence 
of NCD risk factors such as hypertension.3 
Key questions
What is already known about this topic?
 ► Community health workers (CHWs) represent a 
potentially effective force in helping to address 
the rising burden of noncommunicable disease 
(NCDs) in low-income and middle-income countries 
(LMICs).
 ► There is a lack of data evaluating the effectiveness 
of CHWs in improving outcomes among patients 
with NCDs in LMICs.
What are the new findings?
 ► A CHW-delivered intervention focusing on disease 
management and medication adherence improved 
disease control and adherence to medications 
among patients with diabetes and hypertension 
in rural Mexico, when added to a functioning 
comprehensive primary care system.
 ► These data provide the first prospective evidence 
of the effectiveness of CHWs in improving disease 
outcomes among patients with NCDs in Latin 
America.
recommendations for policy
 ► CHWs have a role in health systems strengthening 
to improve disease outcomes among patients with 
NCDs in LMICs.
 ► Health systems that already provide comprehensive 
clinic-based primary care for patients with NCDs 
can further improve adherence, and clinical 
outcomes, by incorporating CHWs.
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In Mexico, diabetes and ischaemic heart disease are the 
two leading causes of disability-adjusted life years as of 
2015, with a rising prevalence in almost all demographic 
groups.4 5 Studies using national survey data estimate the 
proportion of patients with diabetes meeting definitions 
of clinical control at 8%,6 and 57% among patients with 
hypertension.7 Effective coverage for hypertension, a 
WHO benchmarking tool used by Mexico defined as the 
fraction of potential health gain that can be delivered by 
the health system that is actually delivered, is estimated 
to be 23%.8 Addressing NCDs and NCD risk factors is a 
priority for the Mexican Ministry of Health.4 5
Community health workers (CHWs) play an important 
and growing role in health systems worldwide, and there 
is increasing interest in their role in the global response 
to NCDs.9 10 The best recent evidence of CHWs’ ability to 
improve NCD control comes from studies conducted in 
the USA. A systematic review of randomised controlled 
trials of CHW-led interventions among Latino patients 
with diabetes documented decreases in percent haemo-
globin A1c of 0.37–0.75 as well as improved medication 
adherence when CHWs were added to the standard 
of care,11 and a review among hypertensive patients 
reported significant improvements in blood pressure in 
seven of eight randomised controlled trials.12 Differences 
in patient demographics, health infrastructure and CHW 
roles and responsibilities make it challenging to gener-
alise results from the USA to other settings.
In LMICs, data are limited. There are no studies in 
Latin America examining the effect of CHW-led inter-
ventions on disease outcomes or medication adherence 
among patients with NCDs. Retrospective studies in 
rural Uganda13 and South Africa14 of CHW-led interven-
tions among patients with hypertension have shown an 
association with improved control, and a national-level 
retrospective study in Iran documented improved blood 
pressure and fasting plasma glucose among patients with 
hypertension and diabetes, respectively.15 A CHW-led 
intervention improved blood pressure in hyperten-
sive patients in least one randomised controlled trial, 
conducted in Pakistan.16 A recent systematic review of 
CHW-led interventions for NCDs in LMICs found that 
studies had significant limitations due to study design, 
high loss to follow-up, failure to report important health 
outcomes or inappropriate statistical analysis, which limit 
current understanding of the impact of CHWs in these 
settings.17
There is no national-level CHW programme in Mexico to 
address NCDs or NCD risk factors, but national strategies 
emphasise active community participation in addressing 
the rising burden of NCDs, advocate for the creation 
of community committees and encourage partnership 
with non-governmental organisations.4 5Compañeros en 
Salud (CES) is a non-governmental organisation working 
in collaboration with the Mexican Ministry of Health in 
Chiapas, Mexico, a state with the lowest overall rates of 
effective health coverage in Mexico.8 In this study, we 
examined whether a CHW-led intervention implemented 
by CES was associated with changes in disease control 
and medication adherence among patients with diabetes 
and/or hypertension. We hypothesised that the inter-
vention would be associated with improvements in these 
outcomes.
MetHods
study design
We conducted a prospective cohort study in the context 
of a programmatic roll-out of a CHW-led intervention. 
Based on positive findings from a pilot programme in 
two neighbouring communities, CES made a program-
matic decision to scale the intervention to four addi-
tional communities in a stepwise fashion. To ensure 
optimal training, implementation and supervision, they 
implemented the intervention in one community at a 
time at 3-month intervals, and to respect equity between 
communities, they determined the order of the roll-out 
at random. Because the planned roll-out of the inter-
vention mirrored that of a stepped-wedge trial,18 we 
emulated this study design by collecting outcomes data 
in all four communities at two occasions at baseline (ie, 
prior to implementation in any of the four communities) 
and prior to each expansion to a new community there-
after. We continued data collection until 12 months after 
the last community received the intervention. Figure 1 
shows the timing of data collection and the CHW-led 
intervention roll-out.
This study was reviewed and approved by institutional 
review boards of the Brigham and Women’s Hospital and 
the Instituto Tecnológico de Monterrey and conforms 
to the principles embodied in the Declaration of 
Helsinki. This study is registered at  ClinicalTrials. gov 
(NCT02549495). Participants provided verbal informed 
consent which was documented in writing by study staff.
study population
We conducted this study in four remote, rural commu-
nities with populations of 1500–2500 people in Chiapas, 
Mexico. Participants were Spanish-speaking. Each 
community had one clinic. Clinics maintain registries of 
patients with NCDs that served as the basis for eligibility 
determination and recruitment. Eligible patients were 
those who had a diagnosis of diabetes and/or hyperten-
sion, resided in a study community, were aged 18 years 
or older at time of enrolment and were prescribed daily 
medications by the clinic physician for control of their 
diabetes and/or hypertension. We excluded patients with 
secondary hypertension, type 1 diabetes, pregnancy and 
chronic use of glucocorticoids. We also excluded patients 
who, after enrolment but prior to the implementation of 
the intervention in the first community, were removed 
from diabetes or hypertension treatment by their physi-
cian, moved outside the study community, transferred 
care to another health facility or who no longer carried 
a diagnosis of diabetes or hypertension. The study size 
was determined by the number of patients meeting the 
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eligibility criteria in the communities where the interven-
tion was to be rolled-out.
nCd care in the study setting
CES is an affiliate of Partners in Health, a multinational 
non-governmental organisation with experience with 
CHW-led interventions to deliver care for a range of 
medical conditions, including NCDs.19 Since February 
2012, CES partnered with the Mexican Ministry of 
Health to rehabilitate, staff and operate existing govern-
ment primary care clinics. CES provides comprehen-
sive primary care and manages patients with NCDs in 
accordance with national guidelines. The clinic physician 
directs care of patients with NCDs, which includes once-
monthly clinic visits, therapy with common oral medi-
cations for diabetes (biguanides and sulfonylureas) and 
hypertension (ACE inhibitors, beta-blockers, diuretics, 
angiotensin II receptor blockers and calcium channel 
blockers) and community education. Study patients 
had Mexico’s national health insurance and there are 
no direct charges for clinic visits or medications.20 CES 
screens all adults in their catchment area for diabetes 
and hypertension using door-to-door active case finding, 
works with the Ministry of Health and other suppliers 
to eliminate medication stock-outs and provides clinical 
oversight and continuing education to physicians.21
description of CHW activities
The CHW-led intervention designed by CES, titled 
‘Acompañantes’, follows a ‘community-based accompa-
niment’ approach, which has been previously shown to 
be effective in improving medication adherence and 
disease outcomes among patients with HIV.22–24 In this 
approach, CHWs serve as a bridge between clinic and 
patient, promoting medication adherence, reinforcing 
basic disease education, providing psychosocial support 
and promoting active case retention. The CHWs in 
this intervention are women who were nominated at 
community meetings (either by self or community nomi-
nation), wherein CES staff presented the proposal, and 
then selected on the basis of a formal interview process 
focusing on leadership potential, motivation as well as 
basic literacy and education. They were trained in four-
times-weekly group sessions for 1 month, covering basic 
pathophysiology, diagnosis and treatment of chronic 
diseases such as diabetes and hypertension, as well as 
practical training on the elements of a home visit and 
the logistical requirements of the role. They also partic-
ipated in monthly refresher training sessions, covering 
themes such as brief motivational interviewing, recog-
nising emergencies and complications and navigating 
interactions with challenging patients. CHWs work longi-
tudinally with four to eight patients, conducting home 
visits which begin weekly then change in frequency based 
on a collaborative assessment of the patient’s needs by 
the CHW and clinic physician. CHWs escort patients to 
clinic visits and meet regularly with clinic physicians to 
discuss patient management. CHWs are compensated 
with household food and consumable items, worth a 
dollar amount approximately equivalent to the monthly 
stipend given to participants in Prospera (formerly Opor-
tunidades), a Mexican national conditional cash-transfer 
programme.
data collection
Data collection took place from March 2014 to January 
2016 (see figure 1). We measured systolic and diastolic 
blood pressure (blood pressure, in mm Hg) among 
hypertensive patients, and haemoglobin A1c (A1c, in per 
Figure 1 Schematic of stepped-wedge CHW-led intervention roll-out and data collection. CHW, community health workers.
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cent haemoglobin A1c) among patients with diabetes. 
We measured blood pressure using three measurements 
using the Omron HEM 7080IT E automated blood pres-
sure cuff. We measured A1c using the Bayer A1c NOW 
point-of-care device.
We assessed three aspects of self-reported adherence 
using scales adapted from prior studies of adherence 
to long-term therapy.25 26 27 The number of days during 
the last 5 and 30 days in which medication was not taken 
was assessed using 5-day recall and 30-day recall, respec-
tively,25 26 and adherence behaviour was assessed using 
three questions assessed on a Likert scale, similar to the 
CASE adherence index and adapted to the local context: 
"How often do you take your medications in the way your doctor 
instructed?" "How many days a week do you forget to take 
your pills?” and "Some people choose to stop taking their medi-
cations. When was the last time you chose to stop taking your 
medications?"
Study staff visited patients at home and collected 
outcomes data in all communities at baseline and at 
3-month intervals thereafter, timed just prior to the 
roll-out of the intervention in a new community. We also 
administered a questionnaire with basic demographic 
and income information at the time of enrolment. We 
classified patients as exposed to the intervention once 
it had been implemented in their community; however, 
because data collection occurred just prior to imple-
mentation, the first exposed data point for any patient 
was collected 3 months after implementation in their 
community. Local clinicians and programme personnel 
felt the effect of the intervention could be expected 
within 3 months of implementation.
outcome definitions
We defined disease control as A1c <7 for patients with 
diabetes, and blood pressure <140/90 for hypertensive 
patients (<150/90 for patients aged at least 80 years). We 
classified a patient as optimally adherent by 5-day recall if 
s/he took medications on all of the preceding 5 days, and 
by 30-day recall if s/he took medications on at least 28 of 
the preceding 30 days. Adherence behaviour was classi-
fied as optimal if s/he reported perfect adherence (five 
of five possible points on a Likert scale) for two of three 
questions, and at least near-perfect adherence (four or 
more of five possible points on a Likert scale) on the 
third. For patients with diagnoses of both diabetes and 
hypertension, patients were required to meet the defini-
tion of optimally adherent for both sets of medications or 
controlled disease for both diseases.
statistical methods and data analysis
We conducted individual-level mixed effects analyses, 
which included random intercepts for each individual 
and community to adjust variances for clustering. We 
modelled binary outcomes (optimally adherent vs not, 
controlled vs not) using a logit link. Independent vari-
ables included a binary variable to indicate whether the 
person lived in a community that was exposed to the 
intervention at each time point and an indicator vari-
able for time point to flexibly model time and minimise 
residual confounding by time. We conducted stratified 
analyses to examine whether any effect of the interven-
tion depended on disease (diabetes or hypertension) 
or baseline disease control (adherence outcomes only) 
and calculated P values for differences in ORs using 
Cochran’s Q-test for heterogeneity. Outcome assess-
ments for individuals who withdrew from the study for 
any reason were included until the time at which they 
withdrew. We conducted two sensitivity analyses; in the 
first we adjusted for community, and in the second we 
excluded 10 individuals who were removed from diabetes 
and/or hypertension treatment by their providers during 
the study. Analyses were conducted using SAS V.9.3 (Cary 
Institute, Cary, North Carolina, USA). Statistical signifi-
cance was defined at a threshold of P<0.05.
results
overview of enrolment and data completeness
We screened 142 patients identified through NCD 
patient registries, and we recruited and enrolled 122 
who provided informed consent between 26 February 
2014 and 30 April 2014. 14 of these patients (11%) 
were excluded prior to intervention implementation 
(figure 2). Of the 108 patients analysed, 31 (29%) had 
a diagnosis of diabetes, 52 (48%) of hypertension and 
25 (23%) had both diagnoses. Ninety-one patients (84%) 
contributed data through the completion of the study, 
and 10 of 17 (59%) of patients withdrawn from the study 
were withdrawn due to physician discontinuation of 
therapy (figure 2). Of a total of 902 possible data collec-
tion time points corresponding to active study partic-
ipation (ie, excluding data collection that would have 
occurred following a withdrawal), we collected data at 
866 time points (96%).
description of the study cohort
We present baseline demographic and outcomes data in 
table 1. The majority (66%) of patients were female, and 
the median age was 59 years. All three scales recorded 
a majority of patients reporting suboptimal adherence 
(50%–58%) and only 38% of patients had clinically 
controlled disease (17% and 63% among those with a 
diabetes and hypertension diagnosis, respectively).
Clinical control of diabetes and/or hypertension
Relative to no intervention, receipt of the intervention was 
associated with a twofold increase in the odds of disease 
control (time-adjusted OR 2.04, 95% CI 1.15 to 3.62, P=0.02, 
n=864). Figure 3 shows the prevalence of disease control 
over time, by intervention status. While disease control rates 
were higher at the conclusion of the study relative to base-
line, we observed greater fluctuations in these rates over 
time than we did for adherence. In stratified analyses, we 
did not find evidence that the effect of the intervention on 
disease control depended on diagnosis (time-adjusted OR 
1.78, 95% CI 0.58 to 5.44 for diabetes; time-adjusted OR 
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2.47, 95% CI 1.54 to 3.96 for hypertension; P value for inter-
action=0.59).
Adherence outcomes
Relative to no intervention, receipt of the interven-
tion was associated with an 86% increase in the odds of 
optimal adherence measured by 30-day recall (time-ad-
justed OR 1.86, 95% CI 1.15 to 3.02, P=0.01, n=867), 
and more than a twofold increase in the odds of positive 
adherence behaviour (time-adjusted OR 2.29, 95% CI 
1.26 to 4.15, P=0.007, n=866). We did not find a statisti-
cally significant association between receipt of the inter-
vention and self-reported adherence over the very short 
term using 5-day recall (time-adjusted OR 1.14, 95% CI 
0.74 to 1.75, P=0.55, n=865). Figure 4 shows the preva-
lence of adherence over time, by intervention status, for 
each of the three adherence scales. Adherence, as meas-
ured by all three scales, remained consistently high up to 
a year following implementation in the last community. 
In stratified analyses, we found no evidence that the effect 
of the intervention on adherence, measured by any of the 
three scales, depended on disease (results not shown). 
Similarly, the association between intervention receipt and 
optimal adherence, as measured by 5-day or 30-day recall, 
were nearly identical among individuals with and without 
baseline disease control (results not shown). While the 
intervention appeared to exert greater positive influence 
on self-reported adherence behaviour among individuals 
who lacked baseline control (time-adjusted OR 3.17, 95% 
CI 1.31 to 7.72, P=0.01) as compared with those who had 
controlled disease at baseline (time-adjusted OR 1.38, 
95% CI 0.79 to 2.41, P=0.25), this difference was not statis-
tically significant (P value for interaction=0.12).
sensitivity analysis
Adjustment for community tended to slightly attenuate 
effect estimates (5% for disease control and 30-day recall; 
Figure 2 Study enrolment profile. CHW, community health workers. 
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10% for 5-day recall and adherence behaviour), but did 
not change overall interpretation or affect statistical 
significance. Interpretation of findings for primary anal-
yses of adherence and disease control were unchanged 
in sensitivity analyses excluding the 10 individuals who 
were removed from treatment by their providers during 
the study.
dIsCussIon
We found that a CHW-led intervention was associated 
with improved disease control and medication adher-
ence among patients with diabetes and/or hypertension 
when added to the standard of care in rural Mexico. To 
the best of our knowledge, this study is among the first 
prospective studies in any LMIC examining the impact 
of a CHW-led intervention on disease control and adher-
ence to therapy among patients with NCDs and NCD risk 
factors, and the first in Latin America. Our results are 
consistent with evidence from randomised trials in the 
USA and retrospective observational studies in LMICs 
among patients with diabetes and/or hypertension.11–15
By capitalising on a programmatic stepped roll-out 
of the CHW-led intervention, we were able to analyse 
these data as though it were a stepped-wedge trial. This 
robust approach allowed us to address limitations of the 
existing literature of CHW-led interventions for NCDs 
in LMICs.18 Because all subjects have periods in which 
they are unexposed and exposed to the intervention, 
the study is impervious to confounding by stable individ-
ual-level characteristics. Although 16% of participants 
were not retained in the study to the end, the majority 
of patients withdrawn (59% of patients withdrawn and 
9% of all participants) were withdrawn because their 
physician discontinued daily therapy, which may actually 
indicate clinical improvement attributable to the inter-
vention; however, we lacked data to confirm this hypoth-
esis. Sensitivity analyses excluding these individuals were 
consistent with primary analyses. We followed patients for 
almost 2 years, providing data on the trend of effect after 
the immediate postimplementation phase.
Table 1 Baseline characteristics of study population, by community
Overall
n=108 (%)
Community ‘A’
n=43 (%)
Community ‘B’
n=24 (%)
Community ‘C’
n=25 (%)
Community ‘D’
n=16 (%)
Male 37 (34) 19 (44) 5 (21) 6 (24) 7 (44)
Median age (years) (IQR) (n=101) 59 (50–72) 59 (54–72) 54 (48–70) 61 (54–73) 55 (50–71)
Has a radio 66 (61) 30 (70) 12 (50) 17 (68) 7 (44)
Has a car or motorcycle 29 (27) 8 (19) 6 (25) 11 (44) 4 (25)
Type of remuneration for work 
  Salary 6 (6) 1 (2) 0 (0) 1 (4) 4 (25) 
  Day labour 31 (29) 15 (35) 9 (38) 5 (20) 2 (13 
  None 71 (66) 27 (63) 15 (63) 19 (76) 10 (63)
  Diabetes diagnosis 56 (52) 29 (67) 12 (50) 6 (24) 9 (56)
  Hypertension diagnosis 77 (71) 34 (79) 12 (50) 23 (92) 8 (50)
Person on whom I rely most for support: 
  Spouse 74 (69) 29 (67) 20 (83) 13 (52) 12 (75) 
  Child 12 (11) 4 (9) 1 (4) 5 (20) 2 (13) 
  Other relative 18 (17) 9 (21) 3 (13) 4 (16) 2 (13) 
  Neighbour 4 (4) 1 (2) 0 (0) 3 (12) 0 (0)
Controlled diabetes and/or hypertension 41 (38) 18 (42) 6 (25) 15 (60) 2 (13)
Optimally adherent – 5 day recall 45 (42) 23 (53) 8 (33) 8 (32) 6 (38)
Optimally adherent—30-day recall 54 (50) 28 (65) 11 (46) 7 (28) 8 (50)
Optimally adherent— adherence 
behaviour
51 (47) 25 (58) 10 (42) 8 (32) 8 (50)
Figure 3 Per cent disease control among the study 
population over time, by exposure status to community 
health workers-led intervention.
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CHW-led interventions take many forms, and important 
features of any programme must be identified before 
generalising results to another context.28 A key feature 
of the ‘community-based accompaniment’ approach, 
described here for NCDs and previously for other disease 
states,22–24 is that CHWs augment a health system already 
delivering comprehensive primary care, rather than 
‘task-shifting’ or delegation of tasks ordinarily performed 
by other providers. Additional features include a profes-
sionalised, compensated role with defined responsibil-
ities, integration of the CHW into the value chain of 
care being delivered by other providers, a longitudinal 
commitment to patients for the duration of their illness 
and supportive supervision of CHWs. Although this study 
captured only intensive weekly support, future studies 
can explore whether support that is graded to the needs 
of the patients is equally effective. In all, the aim is to 
add new functionality to care delivery, instead of simply 
patching holes in debilitated systems. Our results are 
therefore likely generalisable to health systems that aim 
to do the same.
This study did not attempt to elucidate the mecha-
nism by which CHWs improved clinical control. Possible 
mechanisms include changes in patients’ health-re-
lated behaviours (eg, improved self-management due 
to informational, emotional and instrumental supports 
provided by CHWs), changes in physician behaviour (eg, 
improved management due to the CHW’s knowledge of, 
or advocacy for, their patients within a previously binary 
doctor-patient relationship) and changes in medication 
adherence. We hypothesise that a significant portion 
of the improvements we observed can be explained by 
improved medication adherence. In this study, patterns 
of improvement in adherence appear similar to those 
observed for disease control. Suboptimal adherence to 
therapy impedes NCD control worldwide, and the low 
baseline rates of adherence observed in this study are 
in line with WHO estimates of below 50% adherence 
to long-term therapy in LMICs.29 Difficulty with adher-
ence disproportionately affects patients living in poverty, 
as many of the barriers prompting poor adherence are 
related to social vulnerability and lack of agency. CHWs 
can address many of the common barriers to adherence, 
including supporting self-management, keeping patients 
engaged in care and mobilising social supports. In part-
nership with a health system which eliminates medi-
cation stock-outs, personnel shortages and direct user 
fees, a majority of common barriers to adherence are 
removed.29 30
This study had several limitations. Our relatively 
small sample size precluded separate disease-specific 
subgroup analyses of absolute changes in blood pressure 
and haemoglobin A1c. To maximise statistical power, 
we included individuals with either or both diseases 
and created a disease-specific outcome variable to indi-
cate disease control. Future studies will be important in 
order to gauge the effect size of improvements in blood 
pressure and haemoglobin A1c due to CHW-led inter-
ventions. We observed improved adherence outcomes 
over time, even prior to intervention implementation. 
This may be attributed to ongoing programmatic and 
health system strengthening in all communities over 
the course of the study, to patients’ familiarity with 
adherence scripts, or to some degree of contamina-
tion of the measured effect as CHWs were rolled out to 
neighbouring communities. A related limitation in the 
adherence measures was the use of self-report, which 
is vulnerable to social desirability and recall biases and 
may result in over-reporting adherence. We observed a 
discrepancy between high rates of self-reported adher-
ence and much lower rates of disease control, which 
may be partially explained by overestimation of abso-
lute rates of adherence. Additionally, this discrepancy 
underscores the fact that although clinical outcomes 
improved and compare favourably with national-level 
data in Mexico,6 7 they are still lower than the CES 
programme goal of universal disease control. This 
Figure 4 Per cent optimal adherence over time among the 
study population by 5-day, 30-day and adherence behaviour 
scales, by exposure status to community health workers-led 
intervention.
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likely highlights that beyond treatment support, other 
supporting interventions will be necessary. Such inter-
ventions could do more to improve access to care (ie, 
improving access to insulin) and tackle the social deter-
minants of NCDs (ie, by increasing agency, improving 
food security and access to healthy foods and increasing 
exercise); examples may include supporting early child 
development and education, improving employment 
opportunities, comprehensive strategies for alcohol 
and tobacco control and for reducing salt and sugar 
intake, universal health coverage and other social 
protection programme.3 A reorganisation of the CHW 
programme taking this into consideration is currently 
underway. Nevertheless, any approach that aims to 
comprehensively address the social determinants of 
disease and improve outcomes will require new invest-
ments in order to build and finance truly functional 
health systems. Learning how to maximise the highest 
value inputs while minimising waste will be important 
for sustaining the political will that is often the main 
determinant of sustained financing.
We offer evidence from a prospective study docu-
menting an association between a CHW-led intervention 
and improved clinical control and medication adherence 
among patients with diabetes and/or hypertension in a 
rural Latin American setting. Further investigation is 
warranted to determine which facets of the intervention 
contribute most greatly to its success, as well as whether 
the impact differs among different NCDs. Follow-up 
studies may provide additional important information on 
the optimal duration of the intervention, the long-term 
durability of effect and the return on investment of such 
interventions. Programmes and health systems aiming 
to improve care of patients with NCDs may consider this 
study as supportive evidence for the addition of CHW-led 
interventions to supplement comprehensive primary 
care systems in rural LMICs.
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